RxDoctor Payments DataLook up a doctor →

Scott Cross, MD

Hematology-Oncology · Norfolk, VANPI 1922003763

Payments from drug & device makers

$1,641,795in general payments, 2019–2025

Across 165 payments — averaging $9950.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$1.2M
  • Janssen Research & Development, LLC$202K
  • Genentech, Inc.$174K
  • Merck$10K
  • AstraZeneca$8K
  • E.r. Squibb & Sons, L.L.C.$4K
  • plus $368 from 5 others
$2,971in research payments, 2019–2025

Across 1 payment — averaging $2970.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$3K

What the payments were for

  • Speaking & faculty fees$15039%
  • Food & beverage$10627%
  • Education$13234%

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology-oncology providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$7,430,093
Medicare patients
822
Services billed
194,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide30$519,511
Lenalidomide38$480,018
JakafiRuxolitinib Phosphate15$292,589
ScemblixAsciminib Hydrochloride11$258,898
ImbruvicaIbrutinib20$233,810
VenclextaVenetoclax13$144,734
GilotrifAfatinib Dimaleate12$139,631
CalquenceAcalabrutinib Maleate14$115,475
BrukinsaZanubrutinib11$81,447
EliquisApixaban76$53,440
Abiraterone Acetate11$36,083
XareltoRivaroxaban33$27,128
Acyclovir116$1,595
ValacyclovirValacyclovir Hcl25$1,328
Ondansetron OdtOndansetron26$1,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$4,129$519,51130 claims
AstraZenecaCalquence$7,745$115,47514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other hematology-oncology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →